Horan Capital Advisors’s Novo Nordisk NVO Stock Holding History

Horan Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-350	Closed	-$12K	–	215
2020 Q3	$12K	Buy	+350	New	+$11.7K	0.01%	239
2020 Q1	–	Sell	-500	Closed	-$14K	–	196
2019 Q4	$14K	Hold	500	–	–	0.01%	212
2019 Q3	$13K	Buy	+500	New	+$12.6K	0.01%	221
2019 Q2	–	Sell	-500	Closed	-$13K	–	187
2019 Q1	$13K	Buy	+500	New	+$12.3K	0.01%	216
2017 Q4	–	Sell	-500	Closed	-$12K	–	200
2017 Q3	$12K	Buy	+500	New	+$11.3K	0.01%	251

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Horan Capital Advisors's NVO Position: Q4 2020 in Review

Horan Capital Advisors sold out of Novo Nordisk (NVO) in Q4 2020, closing a stake of 350 shares — an estimated $12K sold.

Horan Capital Advisors first reported a position in NVO in Q3 2017 and held it in 5 quarters. The position peaked at $14K in Q4 2019. 702 funds tracked by Wall St. Rank hold NVO as of Q4 2020.

Horan Capital Advisors reported no remaining Novo Nordisk position as of Q4 2020 after selling out during the quarter.
Horan Capital Advisors sold 350 Novo Nordisk shares in Q4 2020, an estimated $12K.
Horan Capital Advisors first reported a position in Novo Nordisk in Q3 2017 and held it in 5 quarters.
Horan Capital Advisors's Novo Nordisk position peaked at $14K in Q4 2019.
702 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2020.

Based on Horan Capital Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.